What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025Blood

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

View Full Paper

Ask AI

Bookmark

Authors

JYJun Ho YiSamsung Medical Center DYDok Hyun YoonUlsan College YSYang SongNingbo University

Discussion

Member takes

Implication

Observational analysis demonstrated a 76.9% overall response rate in Asian patients with triple-class exposed multiple myeloma, highlighting teclistamab's efficacy and role in infection management.

Key Points

Overall response rate reached 76.9%, with 63.5% achieving a complete response, indicating teclistamab's effectiveness in treating multiple myeloma.
The safety profile was comparable to previous studies, with notable adverse events being cytokine release syndrome, cytopenias, and infections.
Patients switching to biweekly dosing after initial therapy showed sustained benefits, with 24-month progression-free survival at 59.5%.
These findings underscore the importance of managing infections and the potential of teclistamab as a new standard of care for multiple myeloma patients.

Cite This Study

Yi et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de2f https://doi.org/10.1182/blood-2025-5815

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis demonstrated a 76.9% overall response rate in Asian patients with triple-class exposed multiple myeloma, highlighting teclistamab's efficacy and role in infection management.

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Discussion

Member takes

Implication

Key Points

Cite This Study

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider